Linked Life Data

1663576

Source:http://linkedlifedata.com/resource/pubmed/id/1663576

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1663576rdf:typepubmed:Citationlld:pubmed
pubmed-article:1663576lifeskim:mentionsumls-concept:C0206679lld:lifeskim
pubmed-article:1663576lifeskim:mentionsumls-concept:C0003451lld:lifeskim
pubmed-article:1663576lifeskim:mentionsumls-concept:C0682523lld:lifeskim
pubmed-article:1663576lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:1663576lifeskim:mentionsumls-concept:C0042542lld:lifeskim
pubmed-article:1663576lifeskim:mentionsumls-concept:C0445223lld:lifeskim
pubmed-article:1663576lifeskim:mentionsumls-concept:C1552599lld:lifeskim
pubmed-article:1663576lifeskim:mentionsumls-concept:C1704787lld:lifeskim
pubmed-article:1663576lifeskim:mentionsumls-concept:C1579410lld:lifeskim
pubmed-article:1663576lifeskim:mentionsumls-concept:C0207628lld:lifeskim
pubmed-article:1663576pubmed:issue11lld:pubmed
pubmed-article:1663576pubmed:dateCreated1992-3-4lld:pubmed
pubmed-article:1663576pubmed:abstractTextAntiviral potencies against herpes simplex virus type 1 (HSV-1) of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and ten other nucleoside analogues in human embryonic lung fibroblast (HEL) cells were compared with those in Vero cells. 5-Halogenovinylarabinosyluracils, highly active in HEL cells, were inactive against all three laboratory-stocked strains of HSV-1 but exerted moderate antiviral effects on three clinical isolates in Vero cells. The reduction in anti-HSV-1 potencies of other representative nucleoside analogues in Vero cells was much less than those of 5-halogenovinylarabinosyluracils. However, significant antiviral potencies of BV-araU against laboratory strains were observed in other human and monkey fibroblast cells including an immortalized cell line. Significant enhancement of antiviral activity of BV-araU against a laboratory strain and a clinical isolate was demonstrated in Vero cells by the addition of 0.1 microM aminopterin or FUdR, an inhibitor of thymidylate synthesis. The potentiated anti-HSV-1 activity in Vero cells was comparable to the potency in HEL cells without the inhibitor. These results suggested that high activity of thymidylate synthesis and a large thymidylate pool size in Vero cells seem to be related to loss of anti-HSV-1 potency of BV-araU. Original tissue type, species, and the immortality may not be responsible for the reduced antiviral activity of BV-araU in Vero cells.lld:pubmed
pubmed-article:1663576pubmed:languageenglld:pubmed
pubmed-article:1663576pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1663576pubmed:citationSubsetIMlld:pubmed
pubmed-article:1663576pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1663576pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1663576pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1663576pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1663576pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1663576pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1663576pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1663576pubmed:statusMEDLINElld:pubmed
pubmed-article:1663576pubmed:issn0385-5600lld:pubmed
pubmed-article:1663576pubmed:authorpubmed-author:HayashiKKlld:pubmed
pubmed-article:1663576pubmed:authorpubmed-author:MachidaHHlld:pubmed
pubmed-article:1663576pubmed:authorpubmed-author:SuzutaniTTlld:pubmed
pubmed-article:1663576pubmed:authorpubmed-author:NishitaniMMlld:pubmed
pubmed-article:1663576pubmed:issnTypePrintlld:pubmed
pubmed-article:1663576pubmed:volume35lld:pubmed
pubmed-article:1663576pubmed:ownerNLMlld:pubmed
pubmed-article:1663576pubmed:authorsCompleteYlld:pubmed
pubmed-article:1663576pubmed:pagination963-73lld:pubmed
pubmed-article:1663576pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:1663576pubmed:meshHeadingpubmed-meshheading:1663576-...lld:pubmed
pubmed-article:1663576pubmed:meshHeadingpubmed-meshheading:1663576-...lld:pubmed
pubmed-article:1663576pubmed:meshHeadingpubmed-meshheading:1663576-...lld:pubmed
pubmed-article:1663576pubmed:meshHeadingpubmed-meshheading:1663576-...lld:pubmed
pubmed-article:1663576pubmed:meshHeadingpubmed-meshheading:1663576-...lld:pubmed
pubmed-article:1663576pubmed:meshHeadingpubmed-meshheading:1663576-...lld:pubmed
pubmed-article:1663576pubmed:meshHeadingpubmed-meshheading:1663576-...lld:pubmed
pubmed-article:1663576pubmed:meshHeadingpubmed-meshheading:1663576-...lld:pubmed
pubmed-article:1663576pubmed:meshHeadingpubmed-meshheading:1663576-...lld:pubmed
pubmed-article:1663576pubmed:meshHeadingpubmed-meshheading:1663576-...lld:pubmed
pubmed-article:1663576pubmed:meshHeadingpubmed-meshheading:1663576-...lld:pubmed
pubmed-article:1663576pubmed:meshHeadingpubmed-meshheading:1663576-...lld:pubmed
pubmed-article:1663576pubmed:year1991lld:pubmed
pubmed-article:1663576pubmed:articleTitleDifferent antiviral potencies of BV-araU and related nucleoside analogues against herpes simplex virus type 1 in human cell lines and Vero cells.lld:pubmed
pubmed-article:1663576pubmed:affiliationBiology Laboratory, R & D Division, Yamasa Shoyu Co., Ltd., Chiba, Japan.lld:pubmed
pubmed-article:1663576pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1663576lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1663576lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1663576lld:pubmed